Storia in 7 fonti

Why Is Eli Lilly Stock Gaining Wednesday? - Eli Lilly (NYSE:LLY)

Eli Lilly (LLY) beat Q2 earnings expectations & raised 2026 guidance as Mounjaro and Zepbound drove $22.97B in revenue. Read more.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo19 h fa

Why Is Eli Lilly Stock Gaining Wednesday? - Eli Lilly (NYSE:LLY)

Eli Lilly (LLY) beat Q2 earnings expectations & raised 2026 guidance as Mounjaro and Zepbound drove $22.97B in revenue. Read more.

originale

Timeline cronologica

martedì 4 agosto 2026·benzinga.com
Eli Lilly Stock: How To Earn $500 A Month Ahead Of Q2 Earnings - Eli Lilly (NYSE:LLY)
Eli Lilly investors may be eyeing potential gains from the company’s annual dividend yield of 0.62% ($6.92 a year).
mercoledì 5 agosto 2026·forbes.com
Eli Lilly’s Obesity Drugs Drive Massive Revenue Growth
In this week’s edition of InnovationRx, we look at Lilly’s 2Q earnings, a cannabis-derived drug for PTSD, Apnimed’s IPO and more

qz.com

23 h fa

Eli Lilly Q2 2026 earnings beat, raises full-year revenue forecast

Mounjaro revenue jumped 91% to $9.9 billion and Zepbound brought in $4.9 billion as the drugmaker beat Wall Street estimates

Leggi questa versione → originale

zerohedge.com23 h fa

"Momentum Continues": Lilly Jumps After Raising Revenue Outlook On Surging GLP-1 Demand

"At the same time, Lilly is building for the future. With our next-generation weight-loss medicine..."

Leggi questa versione → originale

cnbc.com1 g fa

Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.

Leggi questa versione → originale

morningstar.com23 h fa

Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued…

Lilly Q2 revenue $23B (+48%) led by Mounjaro/Zepbound GLP-1; non-GAAP EPS +33% ($8.38); FY guidance raised to $85-87B. Retatrutide obesity program completes Phase 3 (BLA Q1 2027); four acquisitions (Orna, Ajax, Centessa, Kelonia) plus $4.5B capex intensify growth pipeline.

Leggi questa versione → originale

forbes.com1 g fa

Eli Lilly’s Obesity Drugs Drive Massive Revenue Growth

Eli Lilly Q2 revenue +48% YoY ($23B) driven by GLP-1: Mounjaro +91% ($10B), Zepbound +46% ($5B); retatrutide seeking FDA approval 2027. GLP-1 reshapes pharma capital allocation; for tech managers, signals accelerating clinical AI, supply chain automation, biotech data governance investment.

Leggi questa versione → originale

mercoledì 5 agosto 2026·

cnbc.com

Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.

mercoledì 5 agosto 2026·

morningstar.com

Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress

mercoledì 5 agosto 2026·

endpoints.news

Lilly beats forecasts again as tirzepatide makes up nearly two-thirds of revenue

Lilly posts $23B in Q2 revenue, beating estimates by $3B as tirzepatide hits 64% of revenue; raises full year guidance to $85B–$87B.

mercoledì 5 agosto 2026·

qz.com

Eli Lilly Q2 2026 earnings beat, raises full-year revenue forecast

Mounjaro revenue jumped 91% to $9.9 billion and Zepbound brought in $4.9 billion as the drugmaker beat Wall Street estimates

mercoledì 5 agosto 2026·

zerohedge.com

"Momentum Continues": Lilly Jumps After Raising Revenue Outlook On Surging GLP-1 Demand

"At the same time, Lilly is building for the future. With our next-generation weight-loss medicine..."

mercoledì 5 agosto 2026·

benzinga.com

Why Is Eli Lilly Stock Gaining Wednesday? - Eli Lilly (NYSE:LLY)

Eli Lilly (LLY) beat Q2 earnings expectations & raised 2026 guidance as Mounjaro and Zepbound drove $22.97B in revenue. Read more.

Why Is Eli Lilly Stock Gaining Wednesday? - Eli Lilly (NYSE:LLY)

Timeline cronologica

Eli Lilly Stock: How To Earn $500 A Month Ahead Of Q2 Earnings - Eli Lilly (NYSE:LLY)

Eli Lilly’s Obesity Drugs Drive Massive Revenue Growth

Eli Lilly Q2 2026 earnings beat, raises full-year revenue forecast

"Momentum Continues": Lilly Jumps After Raising Revenue Outlook On Surging GLP-1 Demand

Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued…

Eli Lilly’s Obesity Drugs Drive Massive Revenue Growth

Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress

Lilly beats forecasts again as tirzepatide makes up nearly two-thirds of revenue

Eli Lilly Q2 2026 earnings beat, raises full-year revenue forecast

"Momentum Continues": Lilly Jumps After Raising Revenue Outlook On Surging GLP-1 Demand

Why Is Eli Lilly Stock Gaining Wednesday? - Eli Lilly (NYSE:LLY)